CAJ | 학술논문

目的：观察丹红注射液联合依达拉奉注射液治疗急性脑梗死的临床疗效。方法180例急性脑梗死患者随机分为研究组与对照组,每组90例,对照组在常规治疗基础上给予依达拉奉注射液治疗,研究组在对照组基础上加用丹红注射液治疗,两组治疗周期均为14 d,治疗结束后评定疗效。结果治疗结束后,研究组临床总有效率为92.22%,显著优于对照组的72.22%(P<0.05)；研究组患者神经功能缺损评分显著低于对照组(P<0.05)。结论丹红注射液联合依达拉奉注射液治疗脑梗死的临床疗效确切,值得在临床进行推广。
목적：관찰단홍주사액연합의체랍봉주사액치료급성뇌경사적림상료효。방법180례급성뇌경사환자수궤분위연구조여대조조,매조90례,대조조재상규치료기출상급여의체랍봉주사액치료,연구조재대조조기출상가용단홍주사액치료,량조치료주기균위14 d,치료결속후평정료효。결과치료결속후,연구조림상총유효솔위92.22%,현저우우대조조적72.22%(P<0.05)；연구조환자신경공능결손평분현저저우대조조(P<0.05)。결론단홍주사액연합의체랍봉주사액치료뇌경사적림상료효학절,치득재림상진행추엄。
Objective To observe the clinical effect of Danhong injection combined with edaravone injection in the treatment of acute cerebral infarction. Methods A total of 180 acute cerebral infarction patients were randomly divided into research group and control group, with 90 cases in each group. The control group received additional edaravone injection on the basis of conventional treatment, and the research group received Danhong injection on the basis of treatment for control group. Treatment lasted for 14 d in both groups, and curative effects were evaluated after treatment. Results After treatment, the research group had much higher clinical total effective rate as 92.22% than 72.22% of the control group (P<0.05). The research group had obviously lower national institutes of health stroke scale score than the control group (P<0.05). Conclusion Combination of danhong injection and edaravone injection provides precisely clinical effect in treating cerebral infarction, and it is worth clinical promotion.